3Xu Y,Wang L,He J. Prevalence and control of diabetes in Chinese adults[J].{H}JAMA:the Journal of the American Medical Association,2013,(09):948-859.
4Nathan DM,Buse JB,Davidson MB. Management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes[J].{H}DIABETES CARE,2006,(08):1963-1972.
6Inzucchi SE,Nauck M,Bergenstal RM. Management of hyperglycemia in type 2 diabetes association and the European association for the study of diabetes[J].{H}DIABETES CARE,2012,(06):1364-1379.
7Riddle M,Umpierrez G,DiGenio A. Contributions of basal and postprandial hyperglycemia over a wide rang of A1C levels before and after treatment intensification in type 2 diabetes[J].{H}DIABETES CARE,2011,(12):2508-2514.
8Morales J. Defining the role of insulin detemir in Basal insulin therapy[J].Drug,2007,(17):2557-2584.
9Klein O,Lynge J,Endahl L. Ablumin-bound basal insulin analogues(insulin detemir and NN344):Comparable time action profiles but less variability than insulin glargine in type 2 diabetes[J].Diabetes Obes and Metab,2007.290-299.
10Philis-Tsimikas A. An update on the use of insulin detemir,with a focus on type 2 diabetes (drug evaluation update)[J].Expert Opin Pharmaacother,2008.2181-2195.
